To elucidate and investigate the possible mechanism of the stemness property in EGFR-positive lung cancer, we used YM155, a stemness inhibitor, and investigated its cellular mechanism and potential as an inhibitor of cancer stemness in EGFR-derived cancer stemness models. This evidence concerns the gene EGFR and lung carcinoma.